{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '103', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '8.4.6', 'Disease-related Events and/or Disease-related Outcomes Not Qualifying as', 'AEs or SAEs', 'Efficacy endpoints as outlined in this section will not be reported to the Sponsor, as described', 'in Section 8.4.1.', 'Specifically, the suspected/actual events covered in this exception include any event that is', 'progression of the cancer under study.', 'The Sponsor will monitor unblinded aggregated efficacy endpoint events and safety data to', 'ensure the safety of the participants in the study.', '8.4.7', 'Events of Clinical Interest (ECIs)', 'Selected nonserious and SAEs are also known as ECIs and must be reported to the Sponsor.', 'Events of clinical interest for this study include:', '1.', 'An overdose of pembrolizumab, as defined in Section 8.5, that is not associated with', 'clinical symptoms or abnormal laboratory results.', '2.', 'Any dose over the prescribed dose of lenvatinib associated with an AE.', '3.', 'An elevated AST or ALT lab value that is greater than or equal to 3X the upper limit', 'of normal and an elevated total bilirubin lab value that is greater than or equal to 2X', 'the upper limit of normal and, at the same time, an alkaline phosphatase lab value that', 'is less than 2X the upper limit of normal, as determined by way of protocol-specified', 'laboratory testing or unscheduled laboratory testing.*', '*Note: These criteria are based upon available regulatory guidance documents. The', 'purpose of the criteria is to specify a threshold of abnormal hepatic tests that may', 'require an additional evaluation for an underlying etiology. The study site guidance', 'for assessment and follow-up of these criteria can be found in the Investigator Study', 'File Binder (or equivalent).', '8.5', 'Treatment of Overdose', 'NOTE: After amendment 007-06, lenvatinib and matching placebo were discontinued.', 'This section was left unchanged for reference.', 'For purposes of this study, an overdose will be defined as any dose exceeding the prescribed', 'dose as follows:', 'Pembrolizumab: >5 times the protocol-specified dose.', 'Lenvatinib: any dose above the protocol-specified dose if associated with an adverse', 'event.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '104', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'There is no specific antidote for an overdose of lenvatinib. Due to its high degree of plasma', 'protein binding, lenvatinib is not expected to be dialyzable. Adverse reactions in patients', 'receiving single doses of lenvatinib as high as 40 mg were similar to those in clinical studies', 'at the recommended dose for differentiated thyroid cancer and RCC.', 'No specific information is available on the treatment of overdose of pembrolizumab or', 'lenvatinib. In the event of overdose, the participant should be observed closely for signs of', 'toxicity. Appropriate supportive treatment should be provided if clinically indicated.', 'All reports of pembrolizumab overdose with and without an AE and all reports of lenvatinib', 'overdose with an AE must be reported by the investigator within 24 hours to the Sponsor', 'either by electronic media or paper.', 'Reports of pembrolizumab overdose without any associated clinical symptoms or abnormal', 'laboratory results, should be reported using the terminology \"accidental or intentional', 'overdose without adverse effect.\"', '8.6', 'Pharmacokinetics', 'As of Protocol Amendment 05, the Sponsor has determined that there is sufficient', 'pembrolizumab/lenvatinib PK data in NSCLC participants. Consequently, no further PK', 'samples for pembrolizumab and lenvatinib or ADA samples for pembrolizumab will be', 'collected.', '8.7', 'Pharmacodynamics', 'Pharmacodynamic parameters will not be evaluated in this study.', '8.8', 'Planned Genetic Analysis Sample Collection', 'Samples are to be collected for planned analysis of associations between genetic variants in', 'germline/tumor DNA and drug response. If a documented law or regulation prohibits (or', 'local IRB/IEC does not approve) sample collection for these purposes, then such samples are', 'not be collected at the corresponding sites.', '8.9', 'Biomarkers', 'To identify novel biomarkers, the following biospecimens to support exploratory analyses of', 'cellular components (eg, protein, RNA, DNA, metabolites) and other circulating molecules', 'will be collected from all participants as specified in the SoA:', 'Blood for genetic analysis', 'Newly obtained/archival tissue sample for PD-L1 analysis', 'Sample collection, storage, and shipment instructions for the exploratory biomarker', 'specimens will be provided in the laboratory manual.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}